Camp4 Therapeutics Corp
For the period ended Dec 31, 2025. Filed Mar 5, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 5, 2026
CAMP$4.33-7.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 15. Exhibits, Financial Statement Schedules
Item 15. Exhibits and Financial Statement Schedules
Financial Statements
For a list of the consolidated financial statements and report of Independent Registered Public Accounting Firm (PCAOB ID:42) included herein, see Index to Consolidated Financial Statements on page 108 of this Annual Report, which is incorporated into this Item by reference.
Exhibits
| Exhibit Number | Description of Exhibit | Form | File Number | Date of Filing | Exhibit Number | Filed/Furnished Herewith |
|---|---|---|---|---|---|---|
| 3.1 | Fifth Amended and Restated Certificate of Incorporation of CAMP4 Therapeutics Corporation | 8-K | 001-423665 | 10/15/2024 | 3.1 | |
| 3.2 | Amended and Restated Bylaws of CAMP4 Therapeutics Corporation | 8-K | 001-423665 | 10/15/2024 | 3.2 | |
| 4.1 | Description of Registered Securities | X | ||||
| 4.2 | Third Amended and Restated Investors’ Rights Agreement, by and among the Registrant and certain of its stockholders, dated June 3, 2022 | S-1 | 333-282241 | 9/20/2024 | 4.1 | |
| 4.3 | Warrant to Purchase Stock, by and between Silicon Valley Bank and CAMP4 Therapeutics Corporation (f/k/a Marauder Therapeutics, Inc.), dated January 4, 2017 | S-1 | 333-282241 | 9/20/2024 | 4.2 | |
| 4.4 | Form of Pre-Funded Warrant | 8-K | 001-423665 | 9/10/2025 | 4.1 | |
| 10.1+ | Patent License Agreement by and between CAMP4 Therapeutics Corporation and the Whitehead Institute for Biomedical Research, dated as of October 23, 2019 | S-1 | 333-282241 | 9/20/2024 | 10.1 | |
| 10.2+ | First Amendment to Patent License Agreement by and between CAMP4 Therapeutics Corporation and the Whitehead Institute for Biomedical Research, dated as of December 14, 2021 | S-1 | 333-282241 | 9/20/2024 | 10.2 | |
| 10.3+ | Second Amendment to Patent License Agreement by and between CAMP4 Therapeutics Corporation and the Whitehead Institute for Biomedical Research, dated as of November 7, 2023 | S-1 | 333-282241 | 9/20/2024 | 10.3 | |
| 10.4# | CAMP4 Therapeutics Corporation Amended and Restated 2016 Stock Option and Grant Plan, as amended, and form of award agreements thereunder | S-1 | 333-282241 | 9/20/2024 | 10.4 | |
| 10.5# | CAMP4 Therapeutics Corporation 2024 Equity Incentive Plan | S-1/A | 333-282241 | 10/7/2024 | 10.5 | |
| 10.6# | Form of Non-Qualified Stock Option Award Agreement for Non-Employee Directors under the 2024 Equity Incentive Plan | S-1/A | 333-282241 | 10/7/2024 | 10.6 | |
| 10.7# | Form of Incentive Stock Option Award Agreement under the 2024 Equity Incentive Plan | S-1/A | 333-282241 | 10/7/2024 | 10.7 | |
| 10.8# | Form of Non-Qualified Stock Option Award Agreement under the 2024 Equity Incentive Plan | S-1/A | 333-282241 | 10/7/2024 | 10.8 | |
| Exhibit Number | Description of Exhibit | Form | File Number | Date of Filing | Exhibit Number | Filed/Furnished Herewith |
|---|---|---|---|---|---|---|
| 10.9# | Amended and Restated Employment Agreement by and between CAMP4 Therapeutics Corporation and Josh Mandel-Brehm, dated October 3, 2024 | S-1/A | 333-282241 | 10/7/2024 | 10.9 | |
| 10.10# | CAMP4 Therapeutics Corporation 2024 Employee Stock Purchase Plan | S-1/A | 333-282241 | 10/7/2024 | 10.10 | |
| 10.11# | Form of Indemnification Agreement between the Registrant and each of its directors and executive officers | S-1/A | 333-282241 | 9/26/2024 | 10.11 | |
| 10.12# | CAMP4 Therapeutics Corporation Severance and Change in Control Plan | S-1/A | 333-282241 | 10/7/2024 | 10.12 | |
| 10.13# | CAMP4 Therapeutics Corporation Amended and Restated Non-Employee Director Compensation Policy | 10-Q | 001-423665 | 5/13/2025 | 10.1 | |
| 10.14 | Lease Agreement by and between CAMP4 Therapeutics Corporation and ARE-MA Region 59, LLC, dated October 3, 2019 | S-1 | 333-282241 | 9/20/2024 | 10.14 | |
| 10.15 | First Amendment to Lease by and between CAMP4 Therapeutics Corporation and ARE-MA Region 59, LLC, dated December 22, 2025 | X | ||||
| 10.16 | Lease by and between CAMP4 Therapeutics Corporation and BCSP Pearl East Property LLC, dated January 3, 2023 | S-1 | 333-282241 | 9/20/2024 | 10.15 | |
| 10.17 | Securities Purchase Agreement, dated September 9, 2025, by and among CAMP4 Therapeutics Corporation and the investors party thereto | 8-K | 001-423665 | 9/10/2025 | 10.1 | |
| 10.18 | Registration Rights Agreement, dated September 9, 2025, by and among CAMP4 Therapeutics Corporation and the investors party thereto | 8-K | 001-423665 | 9/10/2025 | 10.2 | |
| 10.19 | Sales Agreement, dated November 10, 2025, by and between CAMP4 Therapeutics Corporation and Leerink Partners LLC | S-3 | 333-291432 | 11/10/2025 | 1.2 | |
| 10.20+ | Research, Collaboration and License Agreement, dated December 17, 2025, by and between CAMP4 Therapeutics Corporation and GlaxoSmithKline Intellectual Property (No. 3) Limited | X | ||||
| 10.21 | Lease Agreement, dated December 22, 2025, by and between CAMP4 Therapeutics Corporation and ARE-MA Region No. 75, LLC | X | ||||
| 10.22# | Form of Inducement Option Award Agreement | X | ||||
| 19.1 | Amended and Restated Insider Trading Policy | 10-Q | 001-423665 | 8/14/2025 | 19.1 | |
| 21.1 | List of Subsidiaries of CAMP4 Therapeutics Corporation | S-1 | 333-282241 | 9/20/2024 | 21.1 | |
| 23.1 | Consent of Ernst & Young LLP, independent registered public accounting firm | X | ||||
| 24.1 | Power of Attorney (included on signature page). | |||||
| 31.1 | Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | X | ||||
| Exhibit Number | Description of Exhibit | Form | File Number | Date of Filing | Exhibit Number | Filed/Furnished Herewith |
|---|---|---|---|---|---|---|
| 31.2 · Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 · X | ||||||
| 32.1* · Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 · X | ||||||
| 32.2* · Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 · X | ||||||
| 97.1 | CAMP4 Therapeutics Corporation Policy for Recoupment of Incentive Compensation | S-1/A | 333-282241 | 10/7/2024 | 10.16 | |
| 101.INS | XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document | X | ||||
| 101.SCH | XBRL Taxonomy Extension Calculation Linkbase Document | X | ||||
| 101.CAL | XBRL Taxonomy Extension Calculation Linkbase Document | X | ||||
| 101.DEF | XBRL Taxonomy Extension Definition Linkbase Document | X | ||||
| 101.LAB | XBRL Taxonomy Extension Label Linkbase Document | X | ||||
| 101.PRE | XBRL Taxonomy Extension Presentation Linkbase Document | X | ||||
| 104 | Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101) | X | ||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.